Recent Quotes (30 days)

You have no recent quotes
chg | %

Finance

Results 1 - 8 of about 8 for David E. Graves
Company Exchange Symbol Last price Quote change Market cap
MTS Systems Corporation NASDAQ MTSC 68.70 -0.44 (-0.64%) 1.02B
MTS Systems Corporation (MTS) is a global supplier of test systems and position sensors. The Company's operations are organized and managed in two business ...
Executive:
David D. Johnson
Achillion Pharmaceuticals, Inc. NASDAQ ACHN 8.62 +0.04 (0.47%) 1.01B
Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's primary business is to discover, develop and commercialize small molecule ...
Executive:
David Apelian MD, Ph.D.
Independent Bank Corporation(MI) NASDAQ IBCP 13.36 -0.01 (-0.07%) 306.89M
Independent Bank Corporation is a bank holding company. The Company owns all of the outstanding stock of Independent Bank (the Bank).
Executive:
David C. Reglin
DTS Inc. NASDAQ DTSI 29.91 -0.21 (-0.70%) 529.08M
DTS, Inc. is an audio technology solutions provider for high-definition entertainment experiences. The Company's audio solutions are designed to enable ...
Executive:
David C. Habiger
Oaktree Capital Group LLC NYSE OAK 53.22 -0.02 (-0.04%) 8.19B
Oaktree Capital Group, LLC (Oaktree) is a global investment manager specializing in alternative investments. The Company manages investments in a range of ...
Executive:
David M. Kirchheimer
Eagle Pharmaceuticals Inc NASDAQ EGRX 80.19 +5.43 (7.26%) 1.25B
Eagle Pharmaceuticals, Inc. (Eagle Pharmaceuticals) is a specialty pharmaceutical company. The Company focused on developing and commercializing injectable ...
Executive:
David E. Riggs
Oaktree Capital Group LLC OTCMKTS OKCMZ
Oaktree Capital Group, LLC (Oaktree) is a global investment management firm focused on alternative markets. Oaktree manages funds in investment strategies ...
Executive:
David M. Kirchheimer
Pulmatrix Inc NASDAQ PULM 9.06 +0.72 (8.63%) 131.50M
Pulmatrix, Inc., formerly Ruthigen, Inc., is a clinical stage biotechnology company. The Company is engaged in developing inhaled therapies to address ...
Executive:
David Maki